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dopamine	 neurons	 by	 oxidative	 mechanisms	 involving	 α-synuclein	 and	mitochondrial	 impairment	 –	
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	 Male/Female	 Age	 Brain	weight	
Postmortem	
Interval	
Control	 5/3	 67	±	5	 1248	±	33	 7.0	±	0.8	
iPD	 6/1	 73	±	4	 1297	±	29	 9.8	±	1.9	
	
To	eliminate	endogenous	fluorescence,	human	tissue	was	pre-treated	with	an	autofluorescence	
eliminating	reagent	according	to	the	manufacturer's	instructions	(Chemicon,	Temecula,	CA).	
	
	
	
	 	
		
	
	
	
Figure	S1.	Active	LRRK2	is	detected	by	PL	in	microglia	in	control	brains	and	is	increased	in	iPD	and	in	
rotenone-treated	rats.	(A)	Colocalization	of	pSer1292	PL	signal	in	Iba1	immunoreactive	microglia	in	
substantia	nigra	from	control	and	iPD	brains.	(B)	Quantification	of	pSer1292	PL	signal	in	Iba1	labeled	
microglia	in	substantia	nigra	from	8	control	and	7	iPD	brains.	Comparison	by	unpaired	2-tail	t-test.	(C)	
Colocalization	of	pSer1292	PL	signal	in	Iba1	immunoreactive	microglia	in	substantia	nigra	from	control	
and	rotenone	treated	rats.	(D)	Quantification	of	pSer1292	PL	signal	in	Iba1	labeled	microglia	in	
substantia	nigra	from	4	control	and	4	rotenone	treated	rat	brains.	Comparison	by	unpaired	2-tail	t-test.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
Figure	S2.	Time	course	of	in	vivo	rotenone-induced	LRRK2	activation	as	assessed	by	pSer1292	PL	signal.	
Note	that	LRRK2	is	significantly	activated	by	1	and	5	days	of	rotenone	treatment,	time	points	before	
there	is	detectable	neurodegeneration.	“Endpoint”,	defined	behaviorally,	typically	occurs	at	10-14	days.	
The	pSer1292	PL	signal	was	significantly	elevated	(p<0.0001,	ANOVA	with	Bonferroni	correction)	
compared	to	vehicle	at	all	time	points.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	S3.	LRRK2	is	activated	by	oligomeric	but	not	monomeric	α-synuclein.	pSer1292	PL	signal	(top	
row)	and	14-3-3:LRRK2	PL	(bottom	row)	in	SNCA-/-	cells	treated	with	vehicle,	monomeric	α-synuclein	or	
oligomeric	α-synuclein.	Note	the	increase	in	pSer1292	PL	signal	and	loss	of	14-3-3:LRRK2	–	indicating	
LRRK2	activation	–	only	in	cells	treated	with	oligomeric	α-synuclein.	The	graph	shows	quantification	of	
the	pSer1292	PL	signal	from	these	experiments	(N=3).	Each	symbol	represents	a	single	cell.	Comparison	
by	ANOVA	with	Bonferroni	correction.		
	
	 	
	
	
Figure	S4.	Rotenone-induced	accumulation	of	pSer129-α-synuclein	is	LRRK2-dependent.	Wildtype	and	
LRRK2-/-	cells	were	treated	with	rotenone	with	or	without	co-treatment	with	1	µM	PF-360.	(A)	
Representative	images	of	pSer129-α-synuclein	immunofluorescence	from	wildtype	and	LRRK2-/-	cells.	
Red,	pSer129-α-synuclein	immunofluorescence.	(B)	Quantification	of	pSer129-α-synuclein	in	wildtype	
and	LRRK2-/-	cells	24	hours	after	treatment	with	vehicle,	rotenone,	or	rotenone	+	PF-360.	Each	symbol	
represents	the	mean	value	of	an	independent	experiment	(each	with	4	technical	replicates)	in	which	
immunoreactivity	was	measured	in	at	least	80	cells.	Analysis	was	by	one-way	ANOVA	with	Sidak's	
multiple	comparisons	test.	
